Latest Listings And Ipos News

Eagle Mountain Mining has requested a voluntary suspension of its ASX-listed securities pending a capital raising announcement, with trading expected to resume by 11 November 2025.

Embark Early Education has announced an off-market takeover bid for Mayfield Childcare, valuing the company at nearly $38 million and offering shareholders a premium over recent prices. The move aims to create a larger childcare group with enhanced resources and educational outcomes.

Light & Wonder, Inc. is set to extend its substantial share repurchase program to include its ASX-listed CHESS Depositary Interests starting November 7, 2025, coinciding with its planned Nasdaq delisting.

REA Group reported a solid start to FY26 with 4% revenue growth and a key acquisition that enhances its AI-driven property technology portfolio. Despite challenges in India, the Australian market’s strong yield growth and product adoption underpin a confident outlook.

The Calmer Co. International Limited announces a leadership change with James S. Tonkin appointed Chairman as the company accelerates its U.S. market growth in natural kava products.

Warriedar Resources shareholders have overwhelmingly approved a scheme of arrangement for acquisition by Capricorn Metals, clearing a key hurdle ahead of final court approval and delisting.

Finexia Financial Group has formally ended preliminary discussions with Salter Brothers regarding a potential reverse listing and is seeking immediate reinstatement of its ASX securities.

ALS Limited has responded to an ASX inquiry regarding the delayed lodgement of key disclosure documents related to performance rights granted to director Malcolm Deane, attributing the delay to human error and outlining steps to reinforce compliance.

FSI’s FY2025 portfolio posted a modest 5.0% return, trailing the ASX All Ordinaries Index, while maintaining dividend growth and planning a strategic move into pre-IPO investments.

James Hardie Industries faces intense scrutiny from the ASX after its share price dropped sharply and trading volumes spiked, prompting urgent questions about undisclosed information.

Chimeric Therapeutics has responded to ASX inquiries regarding the disclosure timing and materiality of new clinical data from its ADVENT-AML trial, emphasizing compliance with continuous disclosure rules and the careful verification of promising patient responses.

Clime Investment Management is issuing free bonus options to shareholders, offering a new opportunity to increase holdings at a fixed exercise price before mid-2026.